Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Clinical Trial of SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Next Previous
Trial Profile

Phase 1 Clinical Trial of SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SEP 786 (Primary)
  • Indications Hypoparathyroidism
  • Focus Adverse reactions

Most Recent Events

  • 18 Feb 2025 According to a Septerna media release, Septernas decision to discontinue this trial follows the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion.
  • 18 Feb 2025 Status changed from recruiting to discontinued, according to a Septerna media release.
  • 20 Nov 2024 According to a Septerna media release, data from both the SAD and MAD portions of the trial are expected in mid-2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top